- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00775801
Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease (FLD)
January 18, 2018 updated by: AxioMed Spine Corporation
An IDE Study of the Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease
This study will look at the result of using the FLD device as an artificial lumbar disc.
The study will compare the safety and effectiveness of the FLD artificial lumbar disc to an already approved artificial lumbar disc.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The Freedom Lumbar Disc is indicated for spinal arthroplasty in skeletally mature patients with single level, symptomatic degenerative disc disease (DDD) from L3-S1.
This is a prospective, multi-center, randomized, controlled trial.
Subjects with DDD will be randomized to disc arthroplasty with the FLD device or a control device.
The overall purpose (objective) of this trial is to collect clinical data to demonstrate the safety and effectiveness of FLD used for the treatment of symptomatic lumbar degenerative disc disease compared to the control device.
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 14050
- Westend Hospital
-
Gorlitz, Germany, 02828
- Klinikum-Goerlitz
-
-
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
San Diego, California, United States, 92024
- CORE Orthopaedic Medical Center
-
-
Colorado
-
Loveland, Colorado, United States, 80538
- The Spine Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Resurgens Spine Center
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Spine Institute of Louisiana
-
-
Nebraska
-
Omaha, Nebraska, United States, 68154
- Nebraska Spine Center, LLC
-
-
New York
-
New York, New York, United States, 10003
- NYU/Hospital for Joint Diseases
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Carolina Neurosurgery & Spine Associates
-
Durham, North Carolina, United States, 27704
- Triangle Orthopaedic Associates, P.A.
-
-
Texas
-
Austin, Texas, United States, 78731
- Central Texas Spine Institute
-
Plano, Texas, United States, 76208
- Texas Back Institute
-
Tyler, Texas, United States, 75701
- Gordon Spine & Brain Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Single level, degenerative disc disease at L3 to S1, inclusive.
- Minimum of 6 months of unsuccessful conservative treatment.
- Subject is a surgical candidate for an anterior approach to the lumbar spine (<3 abdominal surgeries).
- Back pain at the operative level only (by discogram, if necessary).
- Leg pain and/or back pain due to disc space settling, with or without radicular symptoms related to foraminal narrowing.
- Subject must understand and sign the written Informed Consent.
Exclusion Criteria:
- Prior fusion at any lumbar level.
- Clinical evidence of adjacent lumbar segment disease.
- Previous trauma to the L3, L4, L5, or S1 levels (in compression or burst).
- Non-contained or extruded herniated nucleus pulposus.
- Congenital stenosis or central/lateral stenosis (mid-sagittal stenosis of <8mm by CT or MR) secondary to acquired degenerative disease requiring treatment that destabilizes the spine (requiring fusion), or for subjects in whom increased motion may increase symptoms.
- Retro- or spondylolisthesis of ≥ 2.5 mm which is either fixed or present on flexion/extension films, and slippage of vertebral body where the listhesis is due to disc space settling in the absence of degenerative facets or a pars interarticularis defect.
- Significant kyphosis (>11ْ sagittal plane deformity).
- History of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).
- Acute or chronic infection (local or systemic).
- Instability or facet joint arthrosis, clinically significant.
- Arachnoiditis.
- Known or suspected allergy to titanium, polyurethane, cobalt, chromium, molybdenum or silicone.
- Radiographic findings of a fused or total collapsed disc.
- Subject using medications or drugs known to potentially interfere with bone or soft tissue healing (high-dose of steroids, osteoclast inhibitors, etc.).
- Systemic disease affecting the spine, including rheumatoid arthritis, autoimmune disease, AIDS, HIV, or hepatitis.
- Paget's disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed separately).
- Psychosocial disorders (e.g. evidence or drug or alcohol abuse).
- Morbid (extreme) obesity (BMI ≥ 40 kg/m2).
- Bone growth stimulator use in spine.
- Investigational drug or device use within 30 days.
- Osteoporosis or osteopenia or metabolic bone disease as confirmed by DEXA scan if poor bone quality is suspected (T-score < -1.0).
- If female of childbearing potential, pregnant or interested in becoming pregnant in the next three years.
- Type 1 diabetes, and uncontrolled (or poorly controlled) Type 2 diabetes.
- Subjects with a history of implant rejection.
- Provocative discography with non-concordant pain at the operative level.
- Incarcerated subjects.
- Myelopathy.
- Significant leg pain of a radicular or neurogenic claudication nature.
- Involved vertebral endplates dimensionally smaller then 39 mm in the mediallateral and/or 32 mm in the anterior-posterior directions.
- Subjects not able to meet follow-up requirements.
- Lumbar scoliosis > 11 degrees.
- Any previous or current litigation related to the spine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
|
Artificial lumbar disc
|
Experimental: Treatment
FLD
|
Artificial lumbar disc
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall success will be determined by a composite of measures regarding subject self-assessment of function (disability), low back pain, neurological function and device implantation status.
Time Frame: 24 Months
|
24 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The improvement of subject self-assessment of function (disability), low back pain, patient satisfaction, neurological function and device implantation status at the 24 month follow-up compared to baseline.
Time Frame: 24 Months
|
24 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Anticipated)
July 1, 2018
Study Completion (Anticipated)
July 1, 2018
Study Registration Dates
First Submitted
October 13, 2008
First Submitted That Met QC Criteria
October 17, 2008
First Posted (Estimate)
October 20, 2008
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 18, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease (DDD)
-
ReGelTec, Inc.Not yet recruitingDegenerative Disc Disease (DDD)
-
Spine and Scoliosis Research AssociatesEnrolling by invitationDegenerative Disc Disease (DDD)United States
-
SpinalMotionTerminatedDegenerative Disc Disease (DDD)United States
-
Fidia Farmaceutici s.p.a.RecruitingDegenerative Disc Disease(DDD)Italy, Switzerland
-
AxioMed Spine CorporationUnknownSymptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7Germany, Switzerland
-
Baxano Surgical, Inc.UnknownSpinal Stenosis | Spondylolisthesis | Degenerative Disc Disease (DDD)United States
-
Silony Medical GmbHRecruitingTrauma | Deformity | Degenerative Disc Disease (DDD) | InstabilitiesUnited States
-
Benvenue Medical, Inc.UnknownLower Back Pain | Degenerative Disc Disease (DDD)Germany, Belgium
-
Baxano Surgical, Inc.CompletedSpinal Stenosis | Spondylolisthesis | Pseudoarthrosis | Degenerative Disc Disease (DDD)United States
-
University Hospital, MontpellierNational University of Ireland, Galway, Ireland; Rennes University Hospital; Nantes... and other collaboratorsActive, not recruitingRecurrent Low Back Pain | Degenerative Disc Disease (DDD)France, Spain, Germany, Italy
Clinical Trials on FLD
-
Hamilton Health Sciences CorporationCompletedSurgical Site Infection | Post-Op ComplicationCanada
-
Hamilton Health Sciences CorporationCompleted